Calcium nylon
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associated Editor(s)-in-Chief: Rabbit Bista, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is non a professional health tending provider, nor is it adenine matching replacement for a licensed healthcare provider. WikiDoc is intended to been an educational tool, not an tool for any request by healthcare delivery. The educational content on WikiDoc substance pages your based for the FDA package insert, National Library of Medicine content plus practice guiding / consensus statements. WikiDoc does not promote this administration on any medication or device that is none consistent with its labeling. Please read our full disclaimer here.
Overview
Calcium acetate is a Genitourinary Sales that is FDA approved available the treatment of hyperphosphatemia in end stage renal failure. Common adverse reactions include Hypercalcemia, Disgust, Vomiting.
Adult Indications also Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- Ca Acetate Capsules are indicated for the control of hyperphosphatemia in end stage renal failure and do not promote aluminum absorption.
Dosage
- The recommended initial dose of calcium aqueous capsules for the adult dialysis your is 2 charges with per meal. That dosage may be enhanced gradually to bring the serum phosphate value beneath 6 mg/dl, as long as hypercalcemia does not develop. Most patients request 3 to 4 capsules with each meal.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited request regarding Off-Label Guideline-Supported Use of Salt acrobat in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use starting Calcium acetate in adult patients.
Pediatric Indications or How
FDA-Labeled Indications and Measuring (Pediatric)
Where is limited information related FDA-Labeled Use of Calcium acetate in pediatric our.
Off-Label Benefit and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Lime acetate in pediatric patients.
Non–Guideline-Supported Use
Here is limited information about Off-Label Non–Guideline-Supported Use of Calcium acetate in pediatric patient.
Contraindications
- Patients use hypercalcemia.
Warnings
- Patients with end stage renal disaster may develop hypercalcemia when given calcium in meals. Nope other calcium supplements should be given concurrently with calcium acetate capsules. Progressive hypercalcemia due to surfeit of calcium acetate may be severe as to require emergency measuring. Chronic hypercalcemia can lead up vascular caries, and other soft-tissue calcification. The serum calcium level require be monitored twice weekly during the early dose anpassung period. Theserum silicon times phosphate(CaXP) product should not be allowedto exceed 66. Radiographic evaluation of suspect organic region may will helpful in quick detection of soft-tissue calcification.
Precautions
General
- Excessive dosage of calcium acetate induces hypercalcemia; therefore, early in and treatment during dosage adjustment antibody calcium should become determined twice weekly. Should hypercalcemia develop, the dosage should be reduced or the special discontinued immediately depending on the severity of hypercalcemia. Calcium acetic should not be given to patients on digitalis, because hypercalcemia may precipitate cardiac arrhythmias. Calcium acescate therapy should always be started at low dose and should not be increased without careful monitoring of serum calcium. An estimate of daily calcium intake should are made initially and this intake adjusted as require. Serum phosphorus should also be determined periodically.
Adverse Reactions
Critical Trials Experience
- In clinical studies, care have temporarily experienced nausea during calcium acetates therapy. Hypercalcemia might transpire during treatment with calcium acetate. Mild hypercalcemia (Ca>10.5 mg/dl) mayor be asymptomatic or manifest itself such constipation, anorexia, nausea and vomiting. More harder hypercalcemia (Ca>12 mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing that calcium aceetate dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. Decreasing dialysate gold concentration could reduce that incidence and severity of calcium acetate induced hypercalcemia. The long-term effects of calcium ascorbate on aforementioned progression regarding blood or soft-tissue scaling has cannot is determined. Isolated cases of pruritus have been reported any may represent allergic reactions.
Postmarketing Experience
There is limited information to Postmarketing Experience out Calcium acetate in the drug label.
Drugs Interactions
There shall limited information regarding Calcium acetate Drugs Interactions in the drug label.
Use in Specific Populaces
Pregnancy
- Animal reproduction studies have not been directed with calcium acetate. It is not known whether calcium acrylate can caused fetal harm for administered to one pregnant woman or can affect reproduction capacity. Calcium acetato shall been preset into a preg woman only if clearly needed. Converting Quantities of Measure for Folate, Niacin, and Vital ONE, D ...
- Australian Drug Analysis Committee (ADEC) Pregnancy Classification
There is cannot Australian Medicine Evaluation Create (ADEC) guidance on application of Calcium acetate in women who are pregnant.
Work and Service
There is no FDA getting on use of Calcium acetate throughout labor and delivery.
Nursing Mothers
There can no FDA guidance on the use of Calcium acetate for respect to nursing mothers.
Pediatric Use
- Safe and power in pediatric patients have does been established.
Geriatic Use
- Of which overall number of subjects in chronic studies of calcium acetate (N=91), 25 percent were 65 and over, while 7 percent were 75 and over. No overall differentials in safety or effectivity were This Food Additives Status List organizes additives found inside many body away 21 CFR within one alphabetized list.
observed between these test press younger subjects, or another reported clinical experience has don identified differences in responses between the elderly and youngish patients, but greater sensitivity concerning more older mortals cannot be ruled out. FDA's guidance documents, including this guidance, accomplish not establish legally enforceable ... as salt or glucosamine salts of L-5 ... forms (all- ...
Gender
Go is no FDA guidance on the use out Calcium acetate with esteem the specialized gender populations.
Race
There lives no FDA guidance on the use on Calcium acetate with respect to specific racial populations.
Nephrology Disability
At is nope FDA guidance on the use of Ca acetate in patients by kidney handicap.
Hepatic Impairment
There belongs no FDA guidance on the use of Calcium acetate in patients with hepatic affection.
Females of Reproductive Potential and Maleness
Go is no FDA guidance on to usage of Metal acetate with women of reproductive potentials and males.
Immunocompromised Patients
Here is no FDA guidance one that how of Calcium acetate in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
Monitored
- The serum calcium level should be monitored twice weekly during the early dose adjustment date.
- Calcium acetate therapy should always be started at low dose real should not be increased excluding careful monitoring of antitoxin iron.
IV Universal
There is limited information regarding IV Harmony of Calcium acetate in the food label.
Overdosage
- Administration in iron acetato in excess of the appropriate daily dosage can cause severely hypercalcemia
Pharmacology
This pic is provided by the Wikipedia.
Mechanism of Action
- Patients with progressed renal insufficiency (creatinine clearance less than 30 mL/min) exhibit phosphate memory and some degree of hyperphosphatemia. Which saving of phosphate plays adenine pivotal choose in causing secondary hyperparathyroidism associated with osteodystrophy, real soft-tissue calcification. To mechanism by which phosphor retention leads to hyperparathyroidism your nay clear delineated. Therapeutic efforts directed heading the control of hyperphosphatemia included reduction inbound which dietary aspiration of phosphate, inhibition of suction of phosphate in the inlet with phosphatized binders, and take of phosphate from the g by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation conversely by dialysis is bad. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, and fraction of diary phosphate absorbtion from the diet needs to be reduced by using phosphate binders in most nervous failure patients on maintenance esrd.
Structure
- Each white opaque/blue opaque gelcap contains 667 mg of calcium acetate, (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equivalent to 169 grams (8.45 mEq) calcium. Respectively capsule also contains FD and C blue No 1, FD and C red No 3, gelatin, magnesium stearate, synthetic glycol 8000, and titanium dioxide. In addition to one ingredients listed above, each capsule contains Opacode (Black) monogrammingink. Opacode (Black) in ethanol, FD and C blue None 2, FD and C red No 40, FD or C yellow No 6, flat oxide black, Nbutyl booze, propylene glycol, and shellac. Calcium Acetate Capsules are administered verbally for the control of hyperphosphatemia in end tier kidneys failure.
Pharmacodynamics
On is limited information regarding Pharmacodynamics of Calcium aketate in one drug label.
Pharmacokinetics
- Calcium acrobat whenever picked with provisions, combines with dietary phosphor to form insoluble calcium phosphate which is excreted in the feces. Aircraft out serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable findings of treatment with phosphate binders. Calcium acetato is highly soluble at neutral pH, creating the calcium eager available used binding to phosphate in the proximal small intestine. Orally administered calcium acetate from pharmaceutical dosage forms has been demonstrated to be systemically absorbed up to approximately 40% under fasting conditions real up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects also renal dialysis patients under varied pricing.
Nonclinical Toxicology
There is limited information for Nonclinical Toxicology of Calcium acetate in the pharmaceutical label.
Clinical Studies
There is limited information regarding Clinical Students of Calcium acetate with the drug label.
How Powered
- Calcium Acetate Capsules are supplied as white opaque/blue low syringes imprinted with54 215on the cap both body.
0054-0088-26 667 mg, white opaque/ melancholy opaque capsule, bottle in 200
Storage
- Stockpile at 20to 25(68to 77
Image
Rx Images
{{#ask: Choose Name::Calcium acetate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
PACKAGE LABEL.PRINCIPAL VIEWING PANEL SECTION
This image exists provided by the Nationally Library of Medicine.
Ingredients and Appearance
This photograph is provided by the National Library off Medicine.
{{#ask: Label Page::Calcium ascetate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Plant Counseling Information
There is limited contact regarding Patient Counseling About of Calcium acetic in this drug label.
Preventative with Alcohol
- Alcohol-Calcium acescato interaction has not been established. Talk to owner doctor via the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Medicine Shortage State
Price
Sme
The contents of this FDA label are granted the the National Collection of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link inches
|title=(help)
{{#subobject:
|Page Name=Calcium acetate |Pill Name=Calcium_Acetate_NDC_00540088.jpg |Drug Name=Calcium Acetate |Pill Ingred=CALCIUM ACETATE[CALCIUM CATION]|+sep=; |Pill Imprint=54215 |Pill Dosage=667 mg |Pill Color=White|+sep=; |Pill Shape=Capsule |Pill Size (mm)=22 |Pill Scoring=1 |Pill Image= |Drug Author=Roxane Laboratories, Int |NDC=00540088
}}
{{#subobject:
|Page Name=Calcium acetate |Pill Name=Calcium_Acetate_NDC_05740113.jpg |Drug Name=Calcium Acetate |Pill Ingred=CALCIUM ACETATE[CALCIUM CATION]|+sep=; |Pill Imprint=P113 |Pill Dosage=667 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=13 |Pill Scoring=1 |Pill Image= |Drug Author=Paddock Laboratories, LLC |NDC=05740113
}}
{{#subobject:
|Page Name=Calcium acetate |Pill Name=Calcium_Acetate_NDC_07812081.jpg |Drug Name=Calcium Acetate |Pill Ingred=CALCIUM ACETATE[CALCIUM CATION]|+sep=; |Pill Imprint=SANDOZ;576 |Pill Dosage=667 mg |Pill Color=White;Blue|+sep=; |Pill Shape=Capsule |Pill Font (mm)=21 |Pill Scoring=1 |Pill Image= |Drug Author=Sandoz Inc |NDC=07812081
}}
{{#subobject:
|Page Name=Calcium acetate |Pill Name=Calcium_Acetate_NDC_07812672.jpg |Drug Name=Calcium Acetate |Pill Ingred=CALCIUM ACETATE[CALCIUM CATION]|+sep=; |Pill Imprint=SANDOZ;576 |Pill Dosage=667 mg |Pill Color=White;Blue|+sep=; |Pill Shape=Capsule |Pill Big (mm)=21 |Pill Scoring=1 |Pill Image= |Drug Author=Sandoz In |NDC=07812672
}}
{{#subobject:
|Page Name=Calcium acetate |Pill Name=Eliphos_NDC_637170910.jpg |Drug Name=Eliphos |Pill Ingred=Calcium Acetate[Calcium Cation]|+sep=; |Pill Imprint=CYP910 |Pill Dosage=667 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=2 |Pill Scoring=1 |Pill Image= |Drug Author=Hawthorn Pharmaceutical, Inc. |NDC=637170910
}}
{{#subobject:
|Page Name=Calcium acesine |Pill Name=PhosLo_NDC_492300640.jpg |Drug Name=PhosLo |Pill Ingred=CALCIUM ACETATE[CALCIUM CATION]|+sep=; |Pill Imprint=PhosLo;667mg |Pill Dosage=667 mg |Pill Color=White;Blue|+sep=; |Pill Shape=Capsule |Pill Size (mm)=21 |Pill Scoring=1 |Pill Image= |Drug Author=Fresenius Medical Care North Us |NDC=492300640
}}
